Trial Profile
Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 16 Apr 2024
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Radium 223 chloride (Primary) ; Prednisone
- Indications Prostate cancer
- Focus Therapeutic Use
- Acronyms DORA
- 02 Aug 2023 Planned End Date changed from 1 Feb 2026 to 1 Jun 2026.
- 02 Aug 2023 Planned primary completion date changed from 1 Feb 2026 to 1 Jun 2026.
- 20 Feb 2023 Planned End Date changed from 1 Dec 2024 to 1 Feb 2026.